Pierre Fabre Pharmaceuticals Announces Regulatory Update Following Type A Meeting with U.S. Food and Drug Administration (FDA) on Tabelecleucel Biologic License Application (BLA)

B SECAUCUS, N.J., May 7, 2026 /PRNewswire/ — Pierre Fabre Pharmaceuticals, Inc. (PFP), announces it has aligned with FDA on a potential path forward for resubmission…
posteditor
posteditor
Articles: 21727

Other News